| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 2, 2025 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | December 2, 2025 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/18/2025 | $32.00 | Buy | BTIG Research |
| 3/31/2025 | $30.00 | Buy | BofA Securities |
| 3/31/2025 | $29.00 | Outperform | Wolfe Research |
| 3/31/2025 | $24.00 | Neutral | Goldman |
| 3/31/2025 | $28.00 | Buy | Stifel |
| 3/31/2025 | $28.00 | Overweight | Wells Fargo |
| 3/31/2025 | $27.00 | Overweight | Piper Sandler |
BTIG Research initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $32.00
BofA Securities initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $30.00
Goldman initiated coverage of Kestra Medical Technologies with a rating of Neutral and set a new price target of $24.00
KIRKLAND, Wash., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report second quarter fiscal 2026 financial results on Thursday, December 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare
KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the pricing of its upsized underwritten public offering of 6,000,000 common shares at a price to the public of $23.00 per share. The gross proceeds to Kestra from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $138,000,000. In addition, Kestra has granted the underwriters a 30-day option to purchase up to an additional 900,000 common shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close o
KIRKLAND, Wash., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced an underwritten public offering of 5,500,000 common shares. Kestra is offering these shares pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission ("SEC"). Kestra also intends to grant the underwriters a 30-day option to purchase up to an additional 825,000 common shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering ma
4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
424B4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
EFFECT - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
3 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management. "I am pleased to welcome Tim as our Chief Business Officer," said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. "With extensive expertise in cardiac and heart failure innovation, Tim is well positioned to join Kestra at this i
KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company's annual general meeting of shareholders held earlier this month. "I am pleased to welcome Dr. Kwo to the Kestra board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes.
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His
KIRKLAND, Wash., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report second quarter fiscal 2026 financial results on Thursday, December 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare
KIRKLAND, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today reported financial results for the first quarter fiscal 2026, which ended July 31, 2025. Financial Highlights Generated revenue of $19.4 million in Q1 FY26, an increase of 52% compared to the prior year period.Expanded gross margin to 45.7% in Q1 FY26 compared to 32.9% in the prior year period.Increased FY26 revenue guidance to $88 million, representing growth of 47% compared to FY25. "We had a strong start to fiscal 2026, with our sustained commercial momentum generating revenue growth of over 50% in the first quarter," sai
KIRKLAND, Wash., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced that it will report first quarter fiscal 2026 financial results on Thursday, September 11. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website at least 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital h